MHRA Drug Safety Update May 2019

MHRA Drug Safety Update May 2019

May 20, 2019

Date issued: 17th May 2019

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 10 May 2019:1) has been published and includes articles on:

  • Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements.
  • Tofacitinib (Xeljanz ▼) : restriction of 10mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing.
  • Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy.
  • Yellow Card: Please help to reverse the decline in reporting of suspected adverse drug reactions.
  • Letters and drug alerts sent to healthcare professionals in April 2019
  • Medical Device Alerts issued in April 2019

To see the latest MHRA Drug Safety Update in full, visit the website.


Posted in:

More Latest News >